Comparative Pharmacology
Head-to-head clinical analysis: CLARITHROMYCIN versus ETHRIL 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITHROMYCIN versus ETHRIL 500.
CLARITHROMYCIN vs ETHRIL 500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the 23S rRNA component, blocking peptide chain elongation and exerting bacteriostatic or bactericidal effects depending on concentration and organism.
Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.
250-500 mg orally twice daily for 7-14 days; for MAC infection: 500 mg twice daily.
500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.
None Documented
None Documented
Clinical Note
moderateClarithromycin + Levofloxacin
"Clarithromycin may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateClarithromycin + Norfloxacin
"Clarithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClarithromycin + Gemifloxacin
"Clarithromycin may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateClarithromycin + Haloperidol
Terminal elimination half-life: 5-7 hours in adults with normal renal function; prolonged to 8-12 hours in moderate to severe renal impairment; clinical context: allows twice-daily dosing; active metabolite (14-hydroxyclarithromycin) half-life similar.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 6-12 hours in hepatic impairment or overdose.
Renal: approximately 30-40% unchanged; biliary/fecal: approximately 40-50% as metabolites; total renal clearance accounts for about 30-40% of dose; hepatic metabolism contributes to elimination; dose adjustment required in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug and glucuronide conjugate accounts for 90-95% of elimination; biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Clarithromycin may increase the QTc-prolonging activities of Haloperidol."